This week's lacklustre results will strengthen boss Emma Walmsley's case for reform - but also inspire her critics When the American hedge fund Elliott Management took a sizeable stake in GlaxoSmithKline this month, the drugmaker's shares jumped 5% on speculation of a possible shake-up at the company. GSK's chief executive, Emma Walmsley, will face questions over the future of the business, as well as its performance, when she unveils first-quarter results on Wednesday, followed by the annual me...
This week's lacklustre results will strengthen boss Emma Walmsley's case for reform - but also inspire her critics When the American hedge fund Elliott Management took a sizeable stake in GlaxoSmithKline this month, the drugmaker's shares jumped 5% on speculation of a possible shake-up at the company. GSK's chief executive, Emma Walmsley, will face questions over the future of the business, as well as its performance, when she unveils first-quarter results on Wednesday, followed by the annual me...
Share this Article
Recommended